10 completed, 9 unknown, 4 terminated, 3 recruiting. 26 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 26 | Completed 10, Unknown 9, Terminated 4, Recruiting 3 |
Follow Cholestasis: new trials by email Literature Review of Cholestasis trials Research Report on Cholestasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D Deficiency Vitamin D2, Calcitriol - Cholestatic Liver Disease, Chronic Liver Disease (CLD) | Phase 4 | Recruiting | Chulalongkorn University | 54 | 2026-04-28 | 2026-08-03 |
| Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU) Livmarli Oral Product - Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | Phase 4 | Recruiting | Mirum Pharmaceuticals, Inc. | 230 | 2025-09-25 | 2026-06-23 |
| Clinical Study on the Treatment of Elevated Total Bilirubin in Primary Biliary Cholangitis With Baobao Dan Capsule Babaodan Capsule - Primary Biliary Cholangitis | Phase 4 | Unknown | Mei Han | 60 | 2024-04-25 | 2024-04-17 |
| Efficacy of Different Doses of Bezafibrate in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cholangitis UDCA 13-15 mg/kg/day, UDCA 13-15 mg/kg/day + Bezafibrate 400 mg/day, UDCA 13-15 mg/kg/day + Bezafibrate 800 mg/day - Primary Biliary Cholangitis (PBC) | Phase 4 | Completed | Instituto de Biotecnologia de Misiones | 60 | 2023-03-01 | 2026-11-10 |
| Atorvastatin Therapy on Xanthoma in Alagille Syndrome atorvastatin - Alagille Syndrome, Atorvastatin | Phase 4 | Completed | Children's Hospital of Fudan University | 15 | 2022-03-22 | 2026-03-27 |
| A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome Methylprednisolone and Mycophenolate mofetil, Methylprednisolone and azathioprine - Autoimmune Hepatitis, Primary Biliary Cirrhosis | Phase 4 | Unknown | Xiaoli Fan | 78 | 2021-06-16 | 2021-06-21 |
| Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy Cyclosporin A, Mycophenolate Mofetil - Hepatitis, Autoimmune, Primary Biliary Cholangitis | Phase 4 | Unknown | West China Hospital | 89 | 2021-06-16 | 2021-06-22 |
| PBC Induced Fatigue Treated With Thiamine Thiamine, Placebo - Primary Biliary Cirrhosis | Phase 4 | Unknown | Henning Grønbæk | 36 | 2021-05-12 | 2021-05-20 |
| Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy Sulperazon, Teicoplanin, Meropenem Injection - Cholangitis, Secondary Biliary, Treatment Compliance | Phase 4 | Completed | Tongji Hospital | 160 | 2021-05-01 | 2022-04-11 |
| Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1 Ursodeoxycholic acid combined with total glucosides of paeony, Ursodeoxycholic acid only - Hepatitis, Primary Biliary Cholangitis | Phase 4 | Unknown | West China Hospital | 137 | 2021-03-17 | 2021-03-24 |
| Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II Ursodeoxycholic acid, Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone) - Hepatitis, Autoimmune, Primary Biliary Cholangitis | Phase 4 | Unknown | West China Hospital | 90 | 2020-11-01 | 2021-03-22 |
| Clinical Research of Tapering UDCA in PBC Patients With a Complete Response ursodeoxycholic acid - Primary Biliary Cholangitis | Phase 4 | Recruiting | Peking Union Medical College Hospital | 90 | 2020-01-21 | 2025-04-01 |
| Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment Obeticholic Acid (OCA), Placebo - Liver Cirrhosis, Biliary | Phase 4 | Terminated | Intercept Pharmaceuticals | 22 | 2018-06-22 | 2022-09-06 |
| A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis 18-22mg/kg/d Ursodeoxycholic, 13-15mg/kg/d Ursodeoxycholic - Primary Biliary Cholangitis | Phase 4 | Unknown | West China Hospital | 40 | 2018-01-30 | 2018-05-03 |
| Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis S-adenosyl-L-methionine - Primary Biliary Cirrhosis | Phase 4 | Completed | Pomeranian Medical University Szczecin | 24 | 2015-11-01 | 2017-03-28 |
| Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Obeticholic Acid (OCA), Placebo - Liver Cirrhosis, Biliary | Phase 4 | Terminated | Intercept Pharmaceuticals | 334 | 2014-12-26 | 2023-03-09 |
| Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis abatacept - Primary Biliary Cirrhosis | Phase 4 | Completed | Christopher Bowlus, MD | 16 | 2014-09-01 | 2020-04-09 |
| Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Ademetionine 2, Ademetionine 1, Ademetionine 3 - Hepatitis B, Cholestasis | Phase 4 | Unknown | Zhejiang Hisun Pharmaceutical Co. Ltd. | 240 | 2013-11-01 | 2014-05-29 |
| Preventing Cholestasis Using SMOFLipid® SMOFLIPID, INTRALIPID - Cholestasis, Psychomotor Disorders, Developmental | Phase 4 | Completed | Medical University of Vienna | 230 | 2012-06-01 | 2018-01-09 |
| The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent EUS-guided biliary drainage with a hybrid metallic stent - Bile Duct Obstruction, Disorder of Bile Duct Stent | Phase 4 | Completed | Inje University | 27 | 2011-09-01 | 2013-12-02 |
Showing 20 of 26. Sign in to see all of them.
Liver Cirrhosis, Biliary (15) · Hepatitis, Autoimmune (3) · Alagille Syndrome (2) · Fibrosis (2) · Hyperphagia (2) · Pancreatic Neoplasms (2) · Bile Duct Neoplasms (1) · Biliary Atresia (1) · Biliary Tract Neoplasms (1) · Cholangitis (1) · Cholestasis, Intrahepatic (1) · Cholestasis, progressive familial intrahepatic 1 (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Gallbladder Neoplasms (1)
Bile Duct Diseases (26) · Biliary Tract Diseases (26) · Digestive System Diseases (26) · Pathological Conditions, Signs and Symptoms (19) · Liver Diseases (18) · Cholestasis, Intrahepatic (17) · Pathologic Processes (16) · Liver Cirrhosis (15) · Fibrosis (13) · Hepatitis (4) · Signs and Symptoms (4) · Autoimmune Diseases (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)
Ursodeoxycholic Acid (4) · Mycophenolic Acid (2) · SMOFlipid (2) · Soybean Oil (2) · obeticholic acid (2) · soybean oil, phospholipid emulsion (2) · Abatacept (1) · Atorvastatin (1) · Azathioprine (1) · Bezafibrate (1) · Calcitriol (1) · Cyclosporine (1) · Ergocalciferols (1) · In Situ Hybridization, Fluorescence (1) · Lipofundin (1)
West China Hospital (4) · Intercept Pharmaceuticals (2) · Centro Hospitalar de Lisboa Central (1) · Children's Hospital of Fudan University (1) · Christopher Bowlus, MD (1) · Chulalongkorn University (1) · Dr. Falk Pharma GmbH (1) · Henning Grønbæk (1) · Inje University (1) · Instituto de Biotecnologia de Misiones (1) · Medical University of Vienna (1) · Mei Han (1) · Mirum Pharmaceuticals, Inc. (1) · Peking Union Medical College Hospital (1) · Pomeranian Medical University Szczecin (1)
China (9) · Germany (4) · United States (4) · Argentina (3) · Belgium (3) · Italy (3) · South Korea (3) · Spain (3) · Sweden (3) · Australia (2) · Austria (2) · Brazil (2) · Canada (2) · Denmark (2) · Estonia (2)
Li Yang, MD (2) · Andreas Repa, MD (1) · Bo Ohlin, M.D. (1) · Carl-Eric Leijonmarck, M.D. (1) · Christian Rust, MD (1) · Christopher L Bowlus, MD (1) · Claes Rudberg, M.D. (1) · Claes Soderlund, M.D. (1) · Eduard Jonas, M.D. (1) · Eric P Kullman, M.D. (1) · Erik Ness, MD (1) · Erik Svartholm, M.D. (1) · Ervin Toth, M.D. (1) · Feng Jiexiong, Postdoctoral (1)
PMID 10022591, PMID 11906641, PMID 15269615, PMID 18310188, PMID 19687773, PMID 20393276, PMID 21034892, PMID 22683686, PMID 24961544, PMID 25321620, PMID 27121784, PMID 29269199, PMID 29415837, PMID 30240471, PMID 31030946, PMID 32590001, PMID 36257349, PMID 37678274, PMID 38551983, PMID 39140490